We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biochip Array Technology Detects Drugs in Oral Fluid

By LabMedica International staff writers
Posted on 09 Aug 2011
A single multiplex assay detects up to 97 drugs and drug metabolites from an undivided oral fluid sample. Matrix dedicated kits ensure reliable assay performance including good specificity, even at lower drug concentrations.

Randox Laboratories (Crumlin, United Kingdom) biochip array technology offers a diagnostic grade testing solution with dependable and reproducible results. The Biochip arrays provide a rapid turnaround time, which is advantageous for onsite workplace drug testing. In comparison, a four-plate automated enzyme linked immunosorbent assay (ELISA) system requires thirteen times longer to process the same results.

A point of collection biochip analyzer was recently launched by Randox--the “Evidence MultiStat,” which processes multiple results in less than twenty minutes. The Biochip platform is multimatrix; therefore, a number of sample types including oral fluid, whole blood, urine, and postmortem tissue can be run on the system. The Randox line of Evidence immunoassay analyzers generate quality control data automatically with every run, ensuring that each test has been carried out successfully.

Randox biochip arrays meet the limit of detection requirements for both the European Workplace Drug Testing Society (EWDT) guidelines for oral fluid testing (2010) and the Australian and New Zealand procedures for specimen collection and the detection and quantification of drugs in oral fluid AS 4760-2006 (2006).

Testing of oral fluid specimens is becoming increasingly popular in the workplace, prisons, and in drug rehabilitation clinics. With a number of benefits to be gained from onsite testing, oral fluid will continue to be put into practice for drugs of abuse screening. As the prevalence of designer drugs and new variations of drugs enter the market, workplace drug testing is set to increase in a bid to detect and deter use. Oral fluid testing is also used as an aid in clinical diagnosis.

Related Links:
Randox Laboratories
European Workplace Drug Testing Society



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Pan-Cancer Panel
TruSight Oncology 500

Latest Molecular Diagnostics News

DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
09 Aug 2011  |   Molecular Diagnostics

Molecular Diagnostics System Provides Lab-Quality Results at POC
09 Aug 2011  |   Molecular Diagnostics

Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
09 Aug 2011  |   Molecular Diagnostics



PURITAN MEDICAL